Date: Feb 22nd, 2019

NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine

Shanghai, China, February 22nd, 2019. NanoMab published its FIH data for the first 16 patients of 99mTc-NM-01 on Journal of Nuclear Medicine (JNM), titled ‘Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer’.

99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment